{"id":1021366,"date":"2026-11-16T10:48:57","date_gmt":"2026-11-16T15:48:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/"},"modified":"2026-11-16T10:48:57","modified_gmt":"2026-11-16T15:48:57","slug":"blackstone-life-sciences-announces-750-million-rd-funding-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/","title":{"rendered":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBlackstone announced today that funds managed by Blackstone Life Sciences (\u201cBlackstone\u201d) will provide $750 million in development funding to Johnson &amp; Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (\u201cOllin\u201d).<\/p>\n<p>\n\u201cWe are pleased to expand our relationship with Johnson &amp; Johnson by supporting the Phase 3 development of OLN324,\u201d said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. \u201cOur financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients\u2019 lives.\u201d<\/p>\n<p>\n\u201cOLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients,\u201d said Kiran Reddy, Senior Managing Director at Blackstone Life Sciences. \u201cWe are excited to work with Johnson &amp; Johnson to help advance this promising new treatment option to patients.\u201d<\/p>\n<p>\nThe agreement is subject to the acquisition of Ollin by Johnson &amp; Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.<\/p>\n<p><b>About Blackstone Life Sciences<\/b><\/p>\n<p>\nBlackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients\u2019 lives and currently has $18 billion in assets under management.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261115269157\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261115269157\/en\/<\/a><\/span><\/p>\n<p>\nDavid Vitek<br \/>\n<br \/>(212) 583-5291<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:David.Vitek@Blackstone.com\">David.Vitek@Blackstone.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Finance Professional Services Other Health General Health Health Asset Management Science Other Science Other Professional Services<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261115269157\/en\/286215\/3\/bx_logo_jpeg.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Blackstone announced today that funds managed by Blackstone Life Sciences (\u201cBlackstone\u201d) will provide $750 million in development funding to Johnson &amp; Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (\u201cOllin\u201d). \u201cWe are pleased to expand our relationship with Johnson &amp; Johnson by supporting the Phase 3 development of OLN324,\u201d said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. \u201cOur financing demonstrates our ability to provide capital &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021366","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Blackstone announced today that funds managed by Blackstone Life Sciences (\u201cBlackstone\u201d) will provide $750 million in development funding to Johnson &amp; Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (\u201cOllin\u201d). \u201cWe are pleased to expand our relationship with Johnson &amp; Johnson by supporting the Phase 3 development of OLN324,\u201d said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. \u201cOur financing demonstrates our ability to provide capital &hellip; Continue reading &quot;Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T15:48:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement\",\"datePublished\":\"2026-11-16T15:48:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/\"},\"wordCount\":363,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/\",\"name\":\"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T15:48:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk","og_description":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Blackstone announced today that funds managed by Blackstone Life Sciences (\u201cBlackstone\u201d) will provide $750 million in development funding to Johnson &amp; Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (\u201cOllin\u201d). \u201cWe are pleased to expand our relationship with Johnson &amp; Johnson by supporting the Phase 3 development of OLN324,\u201d said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. \u201cOur financing demonstrates our ability to provide capital &hellip; Continue reading \"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T15:48:57+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement","datePublished":"2026-11-16T15:48:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/"},"wordCount":363,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/","name":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T15:48:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261115269157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blackstone-life-sciences-announces-750-million-rd-funding-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Blackstone Life Sciences Announces $750 Million R&amp;D Funding Agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021366"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}